MORF Live signaler | Maksimer profitt med Getagraph.com

SELG 111094 min ago

@ $37.26

Utstedt: 14 feb 2024 @ 21:46

Avkastning: -24.93%

Forrige signal: feb 14 - 20:06

Forrige signal: Kjøp

Avkastning: 0.38 %

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

Stats
Dagens volum	547 447
Gjennomsnittsvolum	481 926
Markedsverdi	1.40B
EPS	$0 ( 2024-04-23 )
Neste inntjeningsdato	( $-0.950 ) 2024-08-01
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.77
ATR14	$0.0760 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Rogers Bruce	Buy	7 400	Common Stock
2024-03-27	Rogers Bruce	Sell	7 400	Stock Option (right to buy Common Stock)
2024-03-18	Cooper Simon Peter	Buy	170 000	Employee Stock Options (right to buy)
2024-03-18	Cooper Simon Peter	Buy	14 000	Restricted Stock Unit
2024-03-18	Cooper Simon Peter	Buy	7 000	Restricted Stock Unit

INSIDER POWER
69.65
Last 99 transactions
Buy: 2 671 692 \| Sell: 511 174

Volum Korrelasjon

Lang: 0.12 (neutral)

Kort: -0.28 (neutral)

Signal:(46.295) Neutral

Morphic Holding Inc Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Morphic Holding Inc Korrelasjon - Valuta/Råvare

0.66
( moderate )

0.72
( moderate )

0.00
( neutral )

-0.32
( neutral )

-0.29
( neutral )

Morphic Holding Inc Økonomi

Annual	2023
Omsetning:	$521 000
Bruttogevinst:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2023
Omsetning:	$521 000
Bruttogevinst:	$-570 000 (-109.40 %)
EPS:	$-3.59

FY	2022
Omsetning:	$70.81M
Bruttogevinst:	$69.80M (98.58 %)
EPS:	$-1.550

FY	2021
Omsetning:	$19.79M
Bruttogevinst:	$19.79M (100.00 %)
EPS:	$-2.67

Financial Reports:

No articles found.

Morphic Holding Inc

Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases. The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics. Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.